CSL Limited

CSL Limited is an Australia-based biotechnology company. Its shares trade on the Australian Securities Exchange (ASX) under the ticker CSL.

The group consists of three main businesses. CSL Behring processes blood plasma collected from donors to produce therapies such as immunoglobulins, clotting factors and albumin for immune deficiencies, hemophilia and other rare diseases; the company runs an extensive network of plasma collection centers for this business. CSL Seqirus develops seasonal flu vaccines and pandemic preparedness vaccines. CSL Vifor offers medicines for iron deficiency and kidney disease. In 2025 the company announced a plan to list Seqirus as a separate company, then postponed this step because of uncertainty in the US vaccine market.

Plasma collection costs and volumes, immunoglobulin demand, vaccination rates and health policies in the US, and the restructuring program are watched for this stock. The CSL page on Lzzo.com shows the price of the ASX-listed shares on a US dollar basis; Turkish lira, euro or pound sterling options are also available. A historical price chart, technical indicators, the data source and the time of the last update are on the page.